ImmunoGen Inc (NASDAQ:IMGN)

5.58
Delayed Data
As of 4:00pm ET
 -0.08 / -1.41%
Today’s Change
3.10
Today|||52-Week Range
7.77
-24.80%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$1.1B

Company Description

ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA.

Contact Information

ImmunoGen, Inc.
830 Winter Street
Waltham Massachusetts 02451-1477
P:(781) 895-0600
Investor Relations:
1781

Employees

Shareholders

Other institutional57.43%
Mutual fund holders32.42%
Individual stakeholders1.48%

Top Executives

Mark Joseph EnyedyPresident, Chief Executive Officer & Director
Susan AltschullerChief Financial Officer & Senior Vice President
Anna BerkenblitChief Medical Officer & Senior Vice President
Thomas RyllSenior Vice President-Technical Operations
Stacy A. CoenChief Business Officer & Senior Vice President